J
Jack Stone
Researcher at University of Bristol
Publications - 48
Citations - 2792
Jack Stone is an academic researcher from University of Bristol. The author has contributed to research in topics: Population & Medicine. The author has an hindex of 13, co-authored 35 publications receiving 1788 citations.
Papers
More filters
Journal ArticleDOI
Interventions to prevent HIV and Hepatitis C among people who inject drugs: Latest evidence of effectiveness from a systematic review (2011 to 2020).
Norah Palmateer,Victoria Hamill,Anna Bergenstrom,Harriet Bloomfield,Lara Gordon,Jack Stone,Hannah Fraser,Thomas Seyler,Yuejiao Duan,Richard Tran,Kirsten M.A. Trayner,Christopher Biggam,Shanley Smith,Peter Vickerman,Matthew Hickman,Sharon J. Hutchinson +15 more
TL;DR: A 2011 review of reviews as mentioned in this paper assessed the latest evidence on the effectiveness of harm reduction interventions -drug treatment (including opioid agonist therapy [OAT]), needle and syringe programmes (NSP) and other interventions - in the prevention of HCV and HIV transmission, and related measures of infection risk (IRB and injecting frequency [IF]), among PWID.
Journal Article
Global patterns of opioid use and dependence: Population harms, interventions, and future action
Louisa Degenhardt,Jason Grebely,Jack Stone,Matthew Hickman,Peter Vickerman,Brandon D.L. Marshall,Julie Bruneau,Julie Bruneau,Frederick L. Altice,Graeme Henderson,Afarin Rahimi-Movaghar +10 more
Journal Article
Frequency of injecting among people who inject drugs: A systematic review and meta-analysis
Samantha Colledge,Janni Leung,Sarah Larney,Amy Peacock,Jason Grebely,Matthew Hickman,Evan B Cunningham,Adam Trickey,Jack Stone,Peter Vickerman,Louisa Degenhardt +10 more
TL;DR: The prevalence of injecting frequency among PWID is estimated and estimates are compared to current needle-syringe distribution coverage estimates, and socio-demographic and risk characteristics, and harms associated with daily or more injecting are identified.
Journal ArticleDOI
Evaluating the Prevention Benefit of HCV Treatment: Modeling the SToP-C Treatment as Prevention Study in Prisons.
Aaron G Lim,Jack Stone,Behzad Hajarizadeh,Marianne Byrne,Georgina M. Chambers,Natasha K. Martin,Jason Grebely,Gregory J. Dore,Andrew R. Lloyd,Peter Vickerman +9 more
TL;DR: In this paper, the authors used a dynamic model of HCV transmission in prisons to data from each SToP-C prison on incarceration dynamics, injecting drug use, HCV prevalence trends among prison entrants, and subsequent HCV treatment scale-up.
Journal ArticleDOI
Hepatitis C treatment outcomes among people who inject drugs accessing harm reduction settings in Kenya
Matthew J. Akiyama,Lindsey Riback,Mercy Nyakowa,Helgar Musyoki,John Lizcano,Abbe Muller,Chenshu Zhang,Josephine G. Walker,Jack Stone,Peter Vickerman,Peter Cherutich,Ann E. Kurth +11 more
TL;DR: In conclusion, HCV treatment among PWID in an LMIC setting is feasible and DOT may not be sustainable with limited resources.